## TL;DR

AI applied to imaging typically reports AUCs ~0.63–0.97 with variable sensitivity and specificity; molecular/genomic approaches report very high single-study AUCs (up to ~0.98) but lack large-scale validation; fusion/multimodal systems show the largest gains (AUC ≈0.96–0.98) versus single modalities. 

----

## Imaging based approaches

Imaging approaches cover mammography, CT, MRI, ultrasound and digital pathology and mainly use convolutional neural networks, radiomics and ensemble classifiers to detect early lesions. Reported performance varies by modality, task, and study quality; systematic reviews emphasize improved sensitivity but heterogeneous specificity and study designs.

- **Key AI methods** CNNs, radiomics, ensemble and classical ML methods are commonly used in image-based detection tasks and comparisons with radiologists have been reported in large mammography studies [1] [2] [3].  
- **Cancer types studied** Breast (screening mammography), lung (CT nodule detection), prostate (mpMRI), pancreatic and others have the largest datasets and evaluations [3] [2] [4].  
- **Best reported performance**  
  - **Breast screening multimodal imaging (mammography + ultrasound)** achieved AUC 0.968, specificity 96.41%, accuracy 93.78% (95% CIs reported) in a deep-learning multimodal imaging study [5].  
  - **mpMRI for prostate AI** median AUC was 0.88 with median sensitivity 0.86 and specificity 0.83 across 23 studies in a systematic review [4].  
  - **Screening mammography AI CADs** for very early temporal signals had AUCs 0.63–0.67 in longitudinal pre-diagnostic analyses, with low proportions of cancers flagged at long lead times (e.g., ~13–25% flagged at fixed 90% specificity depending on system and years before diagnosis) [6].  
- **Major limitations**  
  - **Heterogeneity of datasets** across scanners, populations and annotation protocols reduces generalizability [4] [2].  
  - **Specificity variability and false positives** remain a concern despite gains in sensitivity in nodule and mammography tasks [2] [6].  
  - **Limited prospective/external validation** and reader‑study differences complicate clinical translation [4] [3].

----

## Genomics based approaches

Genomic and other molecular liquid‑biopsy or biomarker approaches apply ML/ensemble methods, random forests, and deep networks (including 1D‑CNNs for spectral/proteomic signals) and aim to detect tumor-derived signals in blood, urine or serum. Many single‑study reports show strong discrimination but large-scale clinical validation is often missing.

- **Key AI methods** Random forests and gradient-boosted trees for tabular genomic features, 1D‑CNN + LSTM or other deep nets for proteomic/spectral signals, and multivariate ML classifiers for spectral (SERS) fingerprints have been used [7] [8] [9].  
- **Cancer types studied** Multi-cancer early detection (MCED) concepts, lung cancer (cf. serum SERS), pancreatic cancer (urine proteomic markers), and assorted tumor types in MCED reviews are represented [10] [9] [8].  
- **Best reported performance**  
  - **SERS serum artificial‑nose for early NSCLC** reported sensitivity 100% and specificity 98% in the study abstract [9].  
  - **Urine proteomic panel for PDAC** using 1D‑CNN + LSTM reported accuracy 97% and AUC 98% on a 590-sample public dataset [8].  
  - **High upper‑bound AUCs** (up to ~0.993) and accuracies are reported in reviews/meta-analyses across selected genomic/omics AI studies, but these represent best‑case values across heterogeneous reports [11].  
- **Major limitations**  
  - **Lack of large prospective validation and population-level studies** for MCED and many molecular assays limits clinical readiness [10].  
  - **Risk of overfitting and small cohorts** in high‑performance single studies; reproducibility and assay standardization are commonly noted concerns [10] [11].  
  - **Assay and preanalytic variability** (platforms, sample handling) pose challenges for multi‑site deployment [10].

----

## Multimodal approaches

Multimodal systems fuse imaging with genomics, clinical or demographic data and use attention/fusion modules, 3D CNN backbones, or semi‑supervised layer‑wise fusion; these approaches consistently report higher discrimination than single modalities in the supplied studies. Reported improvements are seen across lung and cervical screening applications.

- **Key AI methods** 3D CNN imaging backbones with fully connected clinical branches plus attention‑based fusion, cross‑modal attention networks, and semi‑supervised deep fusion frameworks are the dominant architectures [12] [13] [14].  
- **Cancer types studied** Lung (CT + clinical/demographics), cervical (histopathology/genomics/clinical), and lung radiogenomic studies are examples demonstrating modality fusion benefits [12] [14] [7].  
- **Best reported performance**  
  - **Cervical integrative multi‑modal model** (histopathology + genomics + clinical) reported AUC 0.98, accuracy 95.88%, sensitivity 96%, specificity 94% in the study abstract [14].  
  - **LungGuard fusion model** (low‑dose CT + biomarkers + demographics) reported AUC ≈0.96, sensitivity ≈92%, specificity ≈90% on a ~2,500‑patient multi‑centre dataset [12].  
  - **Radiogenomic fusion in lung** improved AUC to 96.3% versus imaging-alone 91.8% and gene‑expression‑alone 89.7% in a comparative study [7].  
- **Major limitations**  
  - **Integration complexity**: synchronizing heterogeneous data types, missing modalities, and alignment across sites increase engineering and statistical complexity [12] [14].  
  - **Need for external prospective trials** and demonstration of clinical impact in screening workflows remain recurring recommendations [12] [13].  
  - **Computational and data‑governance costs** (labeling, harmonization) and potential overfitting when sample sizes are modest relative to model complexity [14] [12].

----

## Head to head comparisons

Direct within‑study comparisons between imaging, genomics, and fused multimodal models are limited but informative where available; fusion typically outperforms either modality alone in supplied examples.

- **Radiogenomic lung comparison** A study that trained random forests on gene expression and CNNs on CT, then fused modalities, reported AUCs: fusion 96.3%, imaging alone 91.8%, genomics alone 89.7%, demonstrating additive gains from multimodal fusion [7].  
- **Multimodal superiority statements** Cervical and lung fusion studies report multimodal AUCs ≈0.96–0.98 and state significant improvements over unimodal models, although full per‑modality statistics are not always provided in abstracts [14] [13] [12].  
- **Limitations of comparisons** Many papers report only single‑study results or compare to internal unimodal baselines without wide external benchmarking; heterogeneity in datasets, endpoints, and evaluation protocols complicates cross‑study head‑to‑head conclusions [10] [4].  

Insufficient evidence exists in the supplied corpus for large‑scale randomized or prospective trials directly comparing population‑level screening performance across imaging‑only, genomics‑only, and multimodal AI approaches.